{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:07:50Z","timestamp":1773702470235,"version":"3.50.1"},"reference-count":105,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Alpha herpes simplex viruses are an important public health problem affecting all age groups. It can produce from common cold sores and chicken pox to severe conditions like encephalitis or newborn mortality. Although all three subtypes of alpha herpes viruses have a similar structure, the produced pathology differs, and at the same time, the available prevention measures, such as vaccination. While there is an available and efficient vaccine for the varicella-zoster virus, for herpes simplex virus 1 and 2, after multiple approaches from trivalent subunit vaccine to next-generation live-attenuated virus vaccines and bioinformatic studies, there is still no vaccine available. Although there are multiple failed approaches in present studies, there are also a few promising attempts; for example, the trivalent vaccine containing herpes simplex virus type 2 (HSV-2) glycoproteins C, D, and E (gC2, gD2, gE2) produced in baculovirus was able to protect guinea pigs against vaginal infection and proved to cross-protect against HSV-1. Another promising vaccine is the multivalent DNA vaccine, SL-V20, tested in a mouse model, which lowered the clinical signs of infection and produced efficient viral eradication against vaginal HSV-2. Promising approaches have emerged after the COVID-19 pandemic, and a possible nucleoside-modified mRNA vaccine could be the next step. All the approaches until now have not led to a successful vaccine that could be easy to administer and, at the same time, offer antibodies for a long period.<\/jats:p>","DOI":"10.3390\/vaccines11061094","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T01:35:30Z","timestamp":1686620130000},"page":"1094","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Advances in Alpha Herpes Viruses Vaccines for Human"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5927-7069","authenticated-orcid":false,"given":"Madalina","family":"Preda","sequence":"first","affiliation":[{"name":"Department of Microbiology, Parasitology and Virology, Faculty of Midwives and Nursing, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Research Department, Marius Nasta Institute of Pneumology, 050159 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8694-6195","authenticated-orcid":false,"given":"Loredana Sabina Cornelia","family":"Manolescu","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Parasitology and Virology, Faculty of Midwives and Nursing, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Virology, Institute of Virology \u201cStefan S. Nicolau\u201d, 030304 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razvan Daniel","family":"Chivu","sequence":"additional","affiliation":[{"name":"Department of Public Health and Health Management, Faculty of Midwifery and Nursing, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"ref_1","unstructured":"(2023, June 02). Visual Taxonomy Browser|ICTV. Available online: https:\/\/ictv.global\/taxonomy\/visual-browser."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"798927","DOI":"10.3389\/fmicb.2021.798927","article-title":"Developments in Vaccination for Herpes Simplex Virus","volume":"12","author":"Krishnan","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Diefenbach, R.J., and Fraefel, C. (2020). Herpes Simplex Virus: Methods and Protocols, Springer. Methods in Molecular Biology.","DOI":"10.1007\/978-1-4939-9814-2"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2471\/BLT.19.237149","article-title":"Herpes Simplex Virus: Global Infection Prevalence and Incidence Estimates, 2016","volume":"98","author":"James","year":"2020","journal-title":"Bull. World Health Organ."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/OLQ.0000000000000522","article-title":"Herpes Simplex Virus Type 1 Shedding in Tears, and Nasal and Oral Mucosa of Healthy Adults","volume":"43","author":"Ramchandani","year":"2016","journal-title":"Sex. Transm. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/OLQ.0000000000001371","article-title":"Lifetime Medical Costs of Genital Herpes in the United States: Estimates From Insurance Claims","volume":"48","author":"Eppink","year":"2021","journal-title":"Sex. Transm. Dis."},{"key":"ref_7","unstructured":"(2023, January 17). CDC Chickenpox for HCPs, Available online: https:\/\/www.cdc.gov\/chickenpox\/hcp\/index.html."},{"key":"ref_8","unstructured":"Ayoade, F., and Kumar, S. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2042-4280-3-5","article-title":"Herpes Simplex Virus and Varicella Zoster Virus, the House Guests Who Never Leave","volume":"3","author":"Kinchington","year":"2012","journal-title":"Herpesviridae"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/14760584.2021.1960162","article-title":"Current Vaccine Approaches and Emerging Strategies against Herpes Simplex Virus (HSV)","volume":"20","author":"Wijesinghe","year":"2021","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12223-010-0015-8","article-title":"The Role of Electron Microscopy in the Rapid Diagnosis of Viral Infections\u2014Review","volume":"55","year":"2010","journal-title":"Folia Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e1972","DOI":"10.1002\/rmv.1972","article-title":"Human Herpesvirus Portal Proteins: Structure, Function, and Antiviral Prospects","volume":"28","author":"Kornfeind","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"ref_13","first-page":"1","article-title":"The Varicella-Zoster Virus Genome","volume":"Volume 342","author":"Cohen","year":"2010","journal-title":"Current Topics in Microbiology and Immunology"},{"key":"ref_14","unstructured":"Baron, S. (1996). Medical Microbiology, University of Texas Medical Branch at Galveston."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"McElwee, M., Vijayakrishnan, S., Rixon, F., and Bhella, D. (2018). Structure of the Herpes Simplex Virus Portal-Vertex. PLoS Biol., 16.","DOI":"10.1101\/290544"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1080\/21505594.2021.1982373","article-title":"Pathogenesis and Virulence of Herpes Simplex Virus","volume":"12","author":"Zhu","year":"2021","journal-title":"Virulence"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Galli, J.D., Horton, M., Durr, E., Heidecker, G.J., Freed, D., Fridman, A., Wang, D., and Zhang, L. (2022). Evaluation of HSV-2 GE Binding to IgG-Fc and Application for Vaccine Development. Vaccines, 10.","DOI":"10.3390\/vaccines10020184"},{"key":"ref_18","first-page":"14","article-title":"HSV Membrane Glycoproteins, Their Function in Viral Entry and Their Use in Vaccine Studies","volume":"Volume 43","author":"Ryadnov","year":"2019","journal-title":"Amino Acids, Peptides and Proteins"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2217\/fvl.15.85","article-title":"Cell Entry Mechanisms of HSV: What We Have Learned in Recent Years","volume":"10","author":"Agelidis","year":"2015","journal-title":"Future Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/978-1-4614-0980-9_19","article-title":"Procapsid Assembly, Maturation, Nuclear Exit: Dynamic Steps in the Production of Infectious Herpesvirions","volume":"726","author":"Cardone","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lussignol, M., and Esclatine, A. (2017). Herpesvirus and Autophagy: \u201cAll Right, Everybody Be Cool, This Is a Robbery!\u201d. Viruses, 9.","DOI":"10.3390\/v9120372"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Draganova, E.B., Valentin, J., and Heldwein, E.E. (2021). The Ins and Outs of Herpesviral Capsids: Divergent Structures and Assembly Mechanisms across the Three Subfamilies. Viruses, 13.","DOI":"10.3390\/v13101913"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1073\/pnas.1910537117","article-title":"Abortive Herpes Simplex Virus Infection of Nonneuronal Cells Results in Quiescent Viral Genomes That Can Reactivate","volume":"117","author":"Cohen","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1038\/s41467-020-18537-y","article-title":"Cryo-EM Structure of the Varicella-Zoster Virus A-Capsid","volume":"11","author":"Sun","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Nord\u00e9n, R., Nilsson, J., Samuelsson, E., Risinger, C., Sihlbom, C., Blixt, O., Larson, G., Olofsson, S., and Bergstr\u00f6m, T. (2019). Recombinant Glycoprotein E of Varicella Zoster Virus Contains Glycan-Peptide Motifs That Modulate B Cell Epitopes into Discrete Immunological Signatures. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040954"},{"key":"ref_26","first-page":"155","article-title":"Varicella Zoster Virus Immune Evasion Strategies","volume":"342","author":"Abendroth","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrmicro3215","article-title":"Molecular Mechanisms of Varicella Zoster Virus Pathogenesis","volume":"12","author":"Zerboni","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"18412","DOI":"10.1073\/pnas.1111333108","article-title":"Structure\u2013Function Analysis of Varicella-Zoster Virus Glycoprotein H Identifies Domain-Specific Roles for Fusion and Skin Tropism","volume":"108","author":"Vleck","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gheorghe, A.S., Negru, \u0218.M., Preda, M., Mih\u0103il\u0103, R.I., Komporaly, I.A., Dumitrescu, E.A., Lungulescu, C.V., Kajanto, L.A., Georgescu, B., and Radu, E.A. (2022). Biochemical and Metabolical Pathways Associated with Microbiota-Derived Butyrate in Colorectal Cancer and Omega-3 Fatty Acids Implications: A Narrative Review. Nutrients, 14.","DOI":"10.3390\/nu14061152"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.immuni.2022.04.006","article-title":"The Gut Microbiota Prime Systemic Antiviral Immunity via the CGAS-STING-IFN-I Axis","volume":"55","author":"Erttmann","year":"2022","journal-title":"Immunity"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fcimb.2019.00127","article-title":"Herpes Simplex Virus Evasion of Early Host Antiviral Responses","volume":"9","author":"Tognarelli","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_32","first-page":"7817","article-title":"Association of Hepatitis B Infection in Patients with HIV Encephalopathy","volume":"17","author":"Marinescu","year":"2012","journal-title":"Rom. Biotechnol. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Malik, S., Sah, R., Ahsan, O., Muhammad, K., and Waheed, Y. (2023). Insights into the Novel Therapeutics and Vaccines against Herpes Simplex Virus. Vaccines, 11.","DOI":"10.3390\/vaccines11020325"},{"key":"ref_34","first-page":"e12811","article-title":"SARS-CoV-2 Infection in Seven Childbearing Women at the Moment of Delivery, a Romanian Experience","volume":"13","author":"Radu","year":"2021","journal-title":"Cureus"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3390\/v1030979","article-title":"Innate and Adaptive Immune Responses to Herpes Simplex Virus","volume":"1","author":"Chew","year":"2009","journal-title":"Viruses"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Coco\u015f, R., Mahler, B., Turcu-Stiolica, A., Stoichi\u021b\u0103, A., Ghinet, A., Shelby, E.-S., and Boh\u00eel\u021bea, L.C. (2022). Risk of Death in Comorbidity Subgroups of Hospitalized COVID-19 Patients Inferred by Routine Laboratory Markers of Systemic Inflammation on Admission: A Retrospective Study. Viruses, 14.","DOI":"10.3390\/v14061201"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"617578","DOI":"10.3389\/fcimb.2020.617578","article-title":"Herpes Simplex Virus Cell Entry Mechanisms: An Update","volume":"10","author":"Madavaraju","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1080\/21505594.2021.1980990","article-title":"Herpes Simplex Virus Interference with Immunity: Focus on Dendritic Cells","volume":"12","author":"Ma","year":"2021","journal-title":"Virulence"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-3-319-53168-7_3","article-title":"Innate Immune Mechanisms and Herpes Simplex Virus Infection and Disease","volume":"223","author":"Orzalli","year":"2017","journal-title":"Adv. Anat. Embryol. Cell Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/JVI.02642-15","article-title":"Membrane Perturbation-Associated Ca2+ Signaling and Incoming Genome Sensing Are Required for the Host Response to Low-Level Enveloped Virus Particle Entry","volume":"90","author":"Hare","year":"2016","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1631\/jzus.B1600460","article-title":"Immune Response of T Cells during Herpes Simplex Virus Type 1 (HSV-1) Infection","volume":"18","author":"Zhang","year":"2017","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12612","DOI":"10.1128\/JVI.01930-14","article-title":"Dissection of the Antibody Response against Herpes Simplex Virus Glycoproteins in Naturally Infected Humans","volume":"88","author":"Cairns","year":"2014","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"O\u2019Connor, C.M., and Sen, G.C. (2021). Innate Immune Responses to Herpesvirus Infection. Cells, 10.","DOI":"10.3390\/cells10082122"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1128\/JVI.01211-13","article-title":"Herpes Simplex Virus 1 Ubiquitin-Specific Protease UL36 Inhibits Beta Interferon Production by Deubiquitinating TRAF3","volume":"87","author":"Wang","year":"2013","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"11056","DOI":"10.1128\/JVI.01672-16","article-title":"Herpes Simplex Virus 1 Tegument Protein UL41 Counteracts IFIT3 Antiviral Innate Immunity","volume":"90","author":"Jiang","year":"2016","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fimmu.2019.00373","article-title":"Mechanisms of Immune Control of Mucosal HSV Infection: A Guide to Rational Vaccine Design","volume":"10","author":"Truong","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Manolescu, L.S.C., Zugravu, C., Zaharia, C.N., Dumitrescu, A.I., Prasacu, I., Radu, M.C., Leti\u021bia, G.D., Nita, I., Cristache, C.M., and Gales, L.N. (2022). Barriers and Facilitators of Romanian HPV (Human Papillomavirus) Vaccination. Vaccines, 10.","DOI":"10.3390\/vaccines10101722"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Manolescu, L.S.C., Zaharia, C.N., Dumitrescu, A.I., Prasacu, I., Radu, M.C., Boeru, A.C., Boidache, L., Nita, I., Necsulescu, A., and Medar, C. (2022). COVID-19 Parental Vaccine Hesitancy in Romania: Nationwide Cross-Sectional Study. Vaccines, 10.","DOI":"10.3390\/vaccines10040493"},{"key":"ref_49","first-page":"6439","article-title":"Correlation between Resistance Profile and Immunosuppression in Heavily Treated HIV-1 Infected Romanian Patients","volume":"16","author":"Manolescu","year":"2011","journal-title":"Rom. Biotechnol. Lett."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Preda, M., and Manolescu, L.C.S. (2022). Romania, a Harbour of HIV-1 Subtype F1: Where Are We after 33 Years of HIV-1 Infection?. Viruses, 14.","DOI":"10.3390\/v14092081"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa0904849","article-title":"Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2","volume":"362","author":"Celum","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1128\/AAC.01114-13","article-title":"Rapid Viral Expansion and Short Drug Half-Life Explain the Incomplete Effectiveness of Current Herpes Simplex Virus 2-Directed Antiviral Agents","volume":"57","author":"Schiffer","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Sarkar, B., and Ullah, M.A. (2020). Designing Novel Subunit Vaccines against Herpes Simplex Virus-1 Using Reverse Vaccinology Approach. bioRxiv, Available online: https:\/\/www.biorxiv.org\/content\/10.1101\/2020.01.10.901678v1.full.","DOI":"10.1101\/2020.01.10.901678"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/1743-422X-8-232","article-title":"Design and Evaluation of a Multi-Epitope Assembly Peptide (MEAP) against Herpes Simplex Virus Type 2 Infection in BALB\/c Mice","volume":"8","author":"Wang","year":"2011","journal-title":"Virol. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/JVI.02745-12","article-title":"An Adjuvanted Herpes Simplex Virus 2 Subunit Vaccine Elicits a T Cell Response in Mice and Is an Effective Therapeutic Vaccine in Guinea Pigs","volume":"87","author":"Skoberne","year":"2013","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S906","DOI":"10.1093\/clind\/13.Supplement_11.S906","article-title":"Development of a Herpes Simplex Virus Subunit Glycoprotein Vaccine for Prophylactic and Therapeutic Use [with Discussion]","volume":"13","author":"Burke","year":"1991","journal-title":"Rev. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1086\/374002","article-title":"Herpes Simplex Virus (HSV) Type 2 Glycoprotein D Subunit Vaccines and Protection against Genital HSV-1 or HSV-2 Disease in Guinea Pigs","volume":"187","author":"Bourne","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1016\/j.vaccine.2019.08.077","article-title":"Intranasal Nanoemulsion-Adjuvanted HSV-2 Subunit Vaccine Is Effective as a Prophylactic and Therapeutic Vaccine Using the Guinea Pig Model of Genital Herpes","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e00535-18","DOI":"10.1128\/JVI.00535-18","article-title":"Human Asymptomatic Epitope Peptide\/CXCL10-Based Prime\/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107+ CD8+ T Cells That Infiltrate the Corneas and Trigeminal Ganglia of Humanized HLA Transgenic Rabbits and Protect against Ocular Herpes Challenge","volume":"92","author":"Khan","year":"2018","journal-title":"J. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.vaccine.2015.10.137","article-title":"A Novel HSV-2 Subunit Vaccine Induces GLA-Dependent CD4 and CD8 T Cell Responses and Protective Immunity in Mice and Guinea Pigs","volume":"34","author":"Odegard","year":"2016","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1016\/j.vaccine.2011.09.046","article-title":"Safety and Immunogenicity of Long HSV-2 Peptides Complexed with RhHsc70 in HSV-2 Seropositive Persons","volume":"29","author":"Wald","year":"2011","journal-title":"Vaccine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.vaccine.2018.11.076","article-title":"A Trivalent GC2\/GD2\/GE2 Vaccine for Herpes Simplex Virus Generates Antibody Responses That Block Immune Evasion Domains on GC2 Better than Natural Infection","volume":"37","author":"Hook","year":"2019","journal-title":"Vaccine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/infdis\/158.3.602","article-title":"In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020: Construction and Evaluation in Rodents","volume":"158","author":"Meignier","year":"1988","journal-title":"J. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1172\/JCI116527","article-title":"Replication, Establishment of Latency, and Induced Reactivation of Herpes Simplex Virus Gamma 1 34.5 Deletion Mutants in Rodent Models","volume":"91","author":"Whitley","year":"1993","journal-title":"J. Clin. Invest."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Halford, W.P., P\u00fcschel, R., and Rakowski, B. (2010). Herpes Simplex Virus 2 ICP0\u2212 Mutant Viruses Are Avirulent and Immunogenic: Implications for a Genital Herpes Vaccine. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012251"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1128\/JVI.75.11.5189-5196.2001","article-title":"A Herpes Simplex Virus Type 1 \u039334.5 Second-Site Suppressor Mutant That Exhibits Enhanced Growth in Cultured Glioblastoma Cells Is Severely Attenuated in Animals","volume":"75","author":"Mohr","year":"2001","journal-title":"J. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1016\/j.vaccine.2005.02.028","article-title":"Evaluation of AD472, a Live Attenuated Recombinant Herpes Simplex Virus Type 2 Vaccine in Guinea Pigs","volume":"23","author":"Prichard","year":"2005","journal-title":"Vaccine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1016\/j.vaccine.2018.03.075","article-title":"Intramuscular Vaccination of Guinea Pigs with the Live-Attenuated Human Herpes Simplex Vaccine VC2 Stimulates a Transcriptional Profile of Vaginal Th17 and Regulatory Tr1 Responses","volume":"36","author":"Stanfield","year":"2018","journal-title":"Vaccine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e00616-18","DOI":"10.1128\/JVI.00616-18","article-title":"Immunization by Replication-Competent Controlled Herpesvirus Vectors","volume":"92","author":"Bloom","year":"2018","journal-title":"J. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e88529","DOI":"10.1172\/jci.insight.88529","article-title":"HSV-2 \u0394GD Elicits Fc\u03b3R-Effector Antibodies That Protect against Clinical Isolates","volume":"1","author":"Petro","year":"2016","journal-title":"JCI Insight"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aau6039","article-title":"Maternal Immunization Confers Protection against Neonatal Herpes Simplex Mortality and Behavioral Morbidity","volume":"11","author":"Patel","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41541-020-00254-8","article-title":"The R2 Non-Neuroinvasive HSV-1 Vaccine Affords Protection from Genital HSV-2 Infections in a Guinea Pig Model","volume":"5","author":"Bernstein","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3109\/08820139.2010.534219","article-title":"Immunization with DNA Vaccine Expressing Herpes Simplex Virus Type 1 GD and IL-21 Protects against Mouse Herpes Keratitis","volume":"40","author":"Hu","year":"2011","journal-title":"Immunol. Invest."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"eaaw7083","DOI":"10.1126\/sciimmunol.aaw7083","article-title":"Nucleoside-Modified MRNA Encoding HSV-2 Glycoproteins C, D, E Prevents Clinical and Subclinical Genital Herpes","volume":"4","author":"Awasthi","year":"2019","journal-title":"Sci. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1099\/vir.0.040055-0","article-title":"Vaxfectin-Adjuvanted Plasmid DNA Vaccine Improves Protection and Immunogenicity in a Murine Model of Genital Herpes Infection","volume":"93","author":"Shlapobersky","year":"2012","journal-title":"J. Gen. Virol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8497","DOI":"10.1128\/JVI.01089-15","article-title":"A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens","volume":"89","author":"Awasthi","year":"2015","journal-title":"J. Virol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1128\/JVI.00302-12","article-title":"A Lentiviral Vector-Based, Herpes Simplex Virus 1 (HSV-1) Glycoprotein B Vaccine Affords Cross-Protection against HSV-1 and HSV-2 Genital Infections","volume":"86","author":"Chiuppesi","year":"2012","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e20153741","DOI":"10.1542\/peds.2015-3741","article-title":"Global Varicella Vaccine Effectiveness: A Meta-Analysis","volume":"137","author":"Marin","year":"2016","journal-title":"Pediatrics"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/14760584.2017.1294069","article-title":"Severe Varicella in Persons Vaccinated with Varicella Vaccine (Breakthrough Varicella): A Systematic Literature Review","volume":"16","author":"Leung","year":"2017","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy Results of a Trial of a Herpes Simplex Vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/infdis\/jit651","article-title":"Correlate of Immune Protection Against HSV-1 Genital Disease in Vaccinated Women","volume":"209","author":"Belshe","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Ni\u021b\u0103, I., Ni\u021bipir, C., Toma, \u0218.A., Limb\u0103u, A.M., P\u00eervu, E., B\u0103d\u0103r\u0103u, I.A., Suciu, I., Suciu, G., and Manolescu, L.S.C. (2020). Histological Aspects and Quantitative Assessment of Ki67 as Prognostic Factors in Breast Cancer Patients: Result from a Single-Center, Cross Sectional Study. Medicina, 56.","DOI":"10.3390\/medicina56110600"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.virol.2005.09.020","article-title":"Replication-Defective Viruses as Vaccines and Vaccine Vectors","volume":"344","author":"Dudek","year":"2006","journal-title":"Virology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0092-8674(82)90035-6","article-title":"The Herpes Simplex Virus Amplicon: A New Eucaryotic Defective-Virus Cloning-Amplifying Vector","volume":"30","author":"Spaete","year":"1982","journal-title":"Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/jvi.68.2.689-696.1994","article-title":"Immunization with Replication-Defective Mutants of Herpes Simplex Virus Type 1: Sites of Immune Intervention in Pathogenesis of Challenge Virus Infection","volume":"68","author":"Morrison","year":"1994","journal-title":"J. Virol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.1128\/JVI.74.17.7963-7971.2000","article-title":"Construction, Phenotypic Analysis, and Immunogenicity of a UL5\/UL29 Double Deletion Mutant of Herpes Simplex Virus 2","volume":"74","author":"Kramer","year":"2000","journal-title":"J. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jgm.206","article-title":"Preclinical Safety Testing of DISC-HGMCSF to Support Phase I Clinical Trials in Cancer Patients","volume":"3","author":"Loudon","year":"2001","journal-title":"J. Gene Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1016\/j.vaccine.2022.09.015","article-title":"Cross Protective Efficacy of the Non-Neurotropic Live Attenuated Herpes Simplex Virus Type 1 Vaccine VC-2 Is Enhanced by Intradermal Vaccination and Deletion of Glycoprotein G","volume":"40","author":"Stanfield","year":"2022","journal-title":"Vaccine"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Bernstein, D.I., Cardin, R.D., Pullum, D.A., Bravo, F.J., Kousoulas, K.G., and Dixon, D.A. (2019). Duration of Protection from Live Attenuated vs. Sub Unit HSV-2 Vaccines in the Guinea Pig Model of Genital Herpes: Reassessing Efficacy Using Endpoints from Clinical Trials. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0213401"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.vaccine.2011.01.005","article-title":"Effects of Herpes Simplex Virus Type 2 Glycoprotein Vaccines and CLDC Adjuvant on Genital Herpes Infection in the Guinea Pig","volume":"29","author":"Bernstein","year":"2011","journal-title":"Vaccine"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3109\/02713683.2013.855238","article-title":"A Replication Competent HSV-1(McKrae) with a Mutation in the Amino-Terminus of Glycoprotein K (GK) Is Unable to Infect Mouse Trigeminal Ganglia after Cornea Infection","volume":"39","author":"Saied","year":"2014","journal-title":"Curr. Eye Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1080\/21645515.2020.1749509","article-title":"Herpes Simplex Virus Type 2 Trivalent Protein Vaccine Containing Glycoproteins C, D and E Protects Guinea Pigs against HSV-1 Genital Infection","volume":"16","author":"Egan","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trsl.2021.12.006","article-title":"An MRNA Vaccine to Prevent Genital Herpes","volume":"242","author":"Awasthi","year":"2022","journal-title":"Transl. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.coviro.2014.02.006","article-title":"Status of Prophylactic and Therapeutic Genital Herpes Vaccines","volume":"6","author":"Awasthi","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"104755","DOI":"10.1016\/j.antiviral.2020.104755","article-title":"Multivalent DNA Vaccine Protects against Genital Herpes by T-Cell Immune Induction in Vaginal Mucosa","volume":"177","author":"Kim","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e00335-20","DOI":"10.1128\/JVI.00335-20","article-title":"A Single-Cycle Glycoprotein d Deletion Viral Vaccine Candidate, \u2206gd-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus","volume":"94","author":"Ramsey","year":"2020","journal-title":"J. Virol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.282.4.331","article-title":"Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 Infection: Two Randomized Controlled Trials. Chiron HSV Vaccine Study Group","volume":"282","author":"Corey","year":"1999","journal-title":"JAMA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/B978-0-12-801238-3.10878-5","article-title":"Bioinformatics in Design of Antiviral Vaccines","volume":"15","author":"Nandy","year":"2019","journal-title":"Encycl. Biomed. Eng."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Murata, T. (2021). Human Herpesvirus and the Immune Checkpoint PD-1\/PD-L1 Pathway: Disorders and Strategies for Survival. Microorganisms, 9.","DOI":"10.3390\/microorganisms9040778"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"9428","DOI":"10.3390\/curroncol29120741","article-title":"Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors\u2014A Systematic Review of the Literature","volume":"29","author":"Slavu","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4049\/jimmunol.0902373","article-title":"Early CD4+ T Cell Help Prevents Partial CD8+ T Cell Exhaustion and Promotes Maintenance of Herpes Simplex Virus 1 Latency","volume":"184","author":"Frank","year":"2010","journal-title":"J. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Channappanavar, R., Twardy, B.S., and Suvas, S. (2012). Blocking of PDL-1 Interaction Enhances Primary and Secondary CD8 T Cell Response to Herpes Simplex Virus-1 Infection. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039757"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1016\/j.vaccine.2018.02.067","article-title":"Review of Mathematical Models of HSV-2 Vaccination: Implications for Vaccine Development","volume":"37","author":"Spicknall","year":"2019","journal-title":"Vaccine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.vaccine.2008.11.074","article-title":"Population-Level Effect of Potential HSV2 Prophylactic Vaccines on HIV Incidence in Sub-Saharan Africa","volume":"27","author":"Freeman","year":"2009","journal-title":"Vaccine"},{"key":"ref_105","unstructured":"WHO (2023, May 10). Preferred Product Characteristics for Herpes Simplex Virus Vaccines. Available online: https:\/\/www.who.int\/publications-detail-redirect\/9789241515580."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/6\/1094\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:53:35Z","timestamp":1760126015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/6\/1094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":105,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["vaccines11061094"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11061094","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]}}}